Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNETs (SEQTOR study)
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Fluorouracil; Streptozocin
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms SEQTOR
- 31 Aug 2018 Biomarkers information updated
- 30 May 2017 Planned End Date changed from 1 Dec 2018 to 1 Jun 2020.
- 30 May 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2020.